Sonoma Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
260
- Stock Symbol
-
SNOA
- Investments
-
2
- Share Price
-
$1.09
- (As of Friday Closing)
Sonoma Pharmaceuticals General Information
Description
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Contact Information
Website
www.sonomapharma.comCorporate Office
- 5445 Conestoga Court
- Suite 150
- Boulder, CO 80301
- United States
Corporate Office
- 5445 Conestoga Court
- Suite 150
- Boulder, CO 80301
- United States
Sonoma Pharmaceuticals Stock Performance
As of 13-Nov-2026, Sonoma Pharmaceuticals’s stock price is $1.09. Its current market cap is $5.52M with 5.06M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.09 | $1.17 | $0.85 - $3.95 | $5.52M | 5.06M | 59.9K | -$1.22 |
Sonoma Pharmaceuticals Financials Summary
As of 30-Jun-2026, Sonoma Pharmaceuticals has a trailing 12-month revenue of $21.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 4,330 | 1,780 | (1,578) | 575 |
| Revenue | 21,920 | 19,529 | 14,288 | 12,735 |
| EBITDA | (2,372) | (3,280) | (2,769) | (4,855) |
| Net Income | (2,264) | (3,175) | (3,457) | (4,835) |
| Total Assets | 18,107 | 13,960 | 13,693 | 14,740 |
| Total Debt | 739 | 842 | 305 | 608 |
Sonoma Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sonoma Pharmaceuticals Comparisons
Industry
Financing
Details
Sonoma Pharmaceuticals Competitors (29)
One of Sonoma Pharmaceuticals’s 29 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| STADA ANZ | Corporation | Sydney, Australia | ||||
| Stada Portugal | Corporation | Lisbon, Portugal | ||||
| Zentiva Group | Private Equity-Backed | Prague, Czech Republic | ||||
| STADA Slovakia | Corporation | Bratislava, Slovakia |
Sonoma Pharmaceuticals Patents
Sonoma Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20150283107-A1 | Methods of treating polycystic ovarian syndrome using chlorogenic acid and inositol | Active | 08-Apr-2014 | ||
| US-9259410-B2 | Methods of treating polycystic ovarian syndrome using chlorogenic acid and inositol | Inactive | 08-Apr-2014 | ||
| CA-2913137-A1 | Stabilized hypochlorous acid solution and use thereof | Inactive | 22-May-2013 | ||
| EP-2999341-A1 | Stabilized hypochlorous acid solution and use thereof | Active | 22-May-2013 | ||
| EP-2999341-A4 | Stabilized hypochlorous acid solution and use thereof | Active | 22-May-2013 | A01N59/00 |
Sonoma Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sonoma Pharmaceuticals Investments (2)
Sonoma Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with MicroSafe Group (Certain Wound Care, Disinfection and Animal Health Care Products) for . The deal was made on 27-Feb-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MicroSafe Group (Certain Wound Care, Disinfection and Animal Health Care Products) | 27-Feb-2020 | Corporate Asset Purchase | Buildings and Property | ||
| U.S. Marketing Rights to Mondoxyne | 01-Jan-2015 | Corporate Asset Purchase | Buildings and Property |
Sonoma Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
42.66 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Sonoma Pharmaceuticals FAQs
-
When was Sonoma Pharmaceuticals founded?
Sonoma Pharmaceuticals was founded in 1999.
-
Where is Sonoma Pharmaceuticals headquartered?
Sonoma Pharmaceuticals is headquartered in Boulder, CO.
-
What is the size of Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals has 260 total employees.
-
What industry is Sonoma Pharmaceuticals in?
Sonoma Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Sonoma Pharmaceuticals a private or public company?
Sonoma Pharmaceuticals is a Public company.
-
What is Sonoma Pharmaceuticals’s stock symbol?
The ticker symbol for Sonoma Pharmaceuticals is SNOA.
-
What is the current stock price of Sonoma Pharmaceuticals?
As of 13-Nov-2026 the stock price of Sonoma Pharmaceuticals is $1.09.
-
What is the current market cap of Sonoma Pharmaceuticals?
The current market capitalization of Sonoma Pharmaceuticals is $5.52M.
-
What is Sonoma Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Sonoma Pharmaceuticals is $21.9M.
-
Who are Sonoma Pharmaceuticals’s competitors?
Evonile Pharma, STADA ANZ, Stada Portugal, Zentiva Group, and STADA Slovakia are some of the 29 competitors of Sonoma Pharmaceuticals.
-
What is Sonoma Pharmaceuticals’s annual earnings per share (EPS)?
Sonoma Pharmaceuticals’s EPS for 12 months was -$1.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
